

Supporting Information

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking,^{*,[a]} Arne Scholz,^[a] Philip Lienau,^[a] Gerhard Siemeister,^[a] Dirk Kosemund,^[a] Rolf Bohlmann,^[a] Hans Briem,^[a] Ildiko Terebesi,^[a] Kirstin Meyer,^[a] Katja Prella,^[a] Karsten Denner,^[a] Ulf Bömer,^[a] Martina Schäfer,^[a] Knut Eis,^[a] Ray Valencia,^[a] Stuart Ince,^[a] Franz von Nussbaum,^[a] Dominik Mumberg,^[a] Karl Ziegelbauer,^[a] Bert Klebl,^[b] Axel Choidas,^[b] Peter Nussbaumer,^[b] Matthias Baumann,^[b] Carsten Schultz-Fademrecht,^[b] Gerd Rührter,^[b] Jan Eickhoff,^[b] and Michael Brands^[a]

cmdc_201700447_sm_miscellaneous_information.zip